id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0325-0007,FDA,FDA-2003-E-0325,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Johnson & Johnson,Rule,Certificate Extending Patent Term,2006-09-15T04:00:00Z,2006,9,,,2025-10-29T23:02:31Z,,0,0,090000648049584d
FDA-2003-E-0325-0006,FDA,FDA-2003-E-0325,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-02-28T05:00:00Z,2006,2,,,2025-10-29T22:57:20Z,,0,0,090000648049584c
FDA-2003-E-0325-0005,FDA,FDA-2003-E-0325,Determination of Regulatory Review Period for Purposes of Patent Extension; ZUBRIN,Notice,General Notice,2005-07-28T04:00:00Z,2005,7,2005-07-28T04:00:00Z,,2025-10-29T22:54:26Z,05-14921,0,0,090000648049584b
FDA-2003-E-0325-0004,FDA,FDA-2003-E-0325,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2005-07-18T04:00:00Z,2005,7,,,2025-10-29T22:50:16Z,,0,0,090000648049584a
FDA-2003-E-0325-0003,FDA,FDA-2003-E-0325,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2005-07-14T04:00:00Z,2005,7,,,2025-10-29T22:47:56Z,,0,0,0900006480495849
FDA-2003-E-0325-0002,FDA,FDA-2003-E-0325,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-04-09T04:00:00Z,2004,4,,,2025-10-29T22:45:37Z,,0,0,0900006480495848
FDA-2003-E-0325-0001,FDA,FDA-2003-E-0325,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-09-04T04:00:00Z,2003,9,,,2025-10-29T22:43:01Z,,0,0,0900006480495837